SOURCE: Mission Investor Relations

Mission Investor Relations

December 06, 2011 08:30 ET

MissionIR Features VistaGen Therapeutics in Exclusive Interview Featuring CEO Shawn Singh

ATLANTA, GA--(Marketwire - Dec 6, 2011) - MissionIR today announces that its interview with Shawn Singh, the Chief Executive Officer of VistaGen Therapeutics (OTCBB: VSTA), is now available online. The complete interview can be heard at http://www.vsta.missionir.com/vsta-12-11.mp3.

Mr. Singh provided a brief overview of the company, its drug rescue business model, collaborations in place, milestones achieved this year as well as plans for 2012, which include listing on a higher exchange. He also discussed the background of the company's executive management team and advisory board.

"Since our inception about thirteen years ago, we have obtained and carefully employed more than $42 million of capital," Mr. Singh stated in the interview. "We have been tremendously resourceful in very challenging times, developing a portfolio of technologies with incredible therapeutic commercial potential across a wide range of applications. In 2012 and beyond, we look to achieve a number of milestones that will advance our company to new heights."

About VistaGen Therapeutics, Inc.

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. Drug rescue involves the combination of human pluripotent stem cell technology with modern medicinal chemistry to generate new chemical variants of once promising small molecule drug candidates that pharmaceutical companies have discontinued during preclinical or early clinical development due to heart or liver toxicity, despite positive efficacy data demonstrating their potential therapeutic and commercial benefits. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans.

In parallel with its drug rescue activities, VistaGen is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform.

Additionally, VistaGen's small molecule drug candidate, AV-101, is in Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. VistaGen plans to initiate Phase 2 clinical development of AV-101 in the fourth quarter of 2012. VistaGen is also exploring opportunities to leverage its current Phase 1 clinical program to enable additional Phase 2 clinical studies of AV-101 for epilepsy, Parkinson's disease and depression. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

For more information on VistaGen, visit the company's website at http://www.vistagen.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://www.MissionIR.com

To connect with MissionIR via Facebook, please visit http://www.Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://www.Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Contact Information